Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific Officer [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
a proprietary targeted protein stabilization platform to develop novel therapeutics for cancer and genetic disorders, today announced the appointment of Adam Hughes, Ph.D., as Chief Scientific Officer. Dr. Hughes previously served as VP of Medicinal Chemistry at Vicinitas. “We continue to make notable progress advancing our proprietary Deubiquitinase Targeting Chimera, or DUBTAC, platform, which is designed to restore aberrantly degraded proteins and deliver new therapeutic options to patients with cancer and genetic disorders,” said Christian Hofmann, Ph.D., Chief Executive Officer of Vicinitas Therapeutics. “Adam has been an integral part of building the platform since the founding of the company, and I'm thrilled to now have him at the helm of our scientific organization as Chief Scientific Officer. His extensive experience discovering heterobifunctional molecules and advancing platform-derived clinical candidates, coupled with his demonstrated leadership skills, will be critical
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Theravance Biopharma, Inc. (NASDAQ: TBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdatePR Newswire
- Theravance Biopharma to Participate in an Upcoming Investor ConferencePR Newswire
- Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024PR Newswire
TBPH
Earnings
- 5/13/24 - Beat
TBPH
Sec Filings
- 5/15/24 - Form 10-Q
- 5/13/24 - Form 8-K
- 5/10/24 - Form 4
- TBPH's page on the SEC website